Corcept Therapeutics Inc. Form 4 Filings

CORCEPT THERAPEUTICS INC (CORT) reported that Roberto Wandenkolk Vieira, President, Oncology, sold 296 shares of common stock on September 16, 2026 at $100.82 per share in an open-market transaction under a Rule 10b5-1 trading plan. After the sale, he held 3,946 shares directly, including 1,347 unvested restricted stock award shares scheduled to vest in full on the one-year anniversary of each grant date subject to conditions.

Corcept Therapeutics Inc. (CORT) reports that Chief Business Officer Gary Charles Robb exercised options for 17,493 shares of common stock on September 17, 2026 at an exercise price of $8.27 per share, converting a fully exercisable option into common shares. Following this transaction, he holds 31,156 common shares directly, including 1,663 shares underlying unvested restricted stock awards that vest on the one-year anniversaries of their grant dates if conditions are met, and continues to hold 182,507 options directly that expire on February 10, 2027. He also has indirect ownership of 39,716 common shares through a revocable trust for which he is trustee, plus additional indirect holdings in custodial accounts for his children, and no Rule 10b5-1 trading plan is reported.

CORCEPT THERAPEUTICS INC (CORT) reported that its Chief Accounting & Technology Officer, Joseph Douglas Lyon, exercised stock options for a total of 10,000 shares of common stock on September 14, 2026, at exercise prices of $11.35 and $13.56 per share, and sold 10,000 shares the same day in open-market or private transactions under a Rule 10b5-1 trading plan.

The sales were executed in two tranches at weighted average prices of $113.32 and $114.12 per share, and the filing notes that Lyon also holds unvested restricted stock awards scheduled to vest one year after their respective grant dates, subject to specified service conditions.

CORCEPT THERAPEUTICS INC (CORT) director James N. Wilson reported indirect sales of a total of 10,000 shares of common stock on September 15, 2026 by the James N. Wilson and Pamela D. Wilson Trust. The shares were sold in open-market transactions under a Rule 10b5-1 trading plan adopted on March 12, 2026, at weighted average prices between $109.66 and $111.705 per share. Wilson has voting power over the trust’s shares under voting agreements and disclaims beneficial ownership except to the extent of his pecuniary interest. The filing also reports indirect holdings of 200,000 shares each in the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust as of September 15, 2026.

CORCEPT THERAPEUTICS INC (CORT) reported that Chief Development Officer William Guyer acquired common stock on September 1, 2026 through company equity programs. He purchased 164 shares under a purchase plan established under the 2024 Incentive Award Plan at $113.38 per share, based on that day's closing price, and received an additional 164 shares as unvested restricted stock awards that will vest in full one year after grant if he remains the beneficial owner of the purchase-plan shares and meets plan requirements. Separate unvested restricted stock awards granted on December 1, 2025, March 2, 2026 and June 1, 2026 also remain outstanding and vest on their respective one-year anniversaries subject to conditions. No Rule 10b5-1 trading plan is reported.

CORCEPT THERAPEUTICS INC (CORT) reported that officer Sean Maduck exercised options for 25,000 shares of common stock on September 1, 2026 at an exercise price of $8.27 per share, then sold 25,000 shares the same day in multiple trades around $114–$116 per share under a Rule 10b5-1 trading plan. He also had 117 shares of common stock withheld on September 2, 2026 to cover tax obligations related to vesting restricted stock units and acquired small additional amounts of stock through a purchase plan and restricted stock awards.

CORCEPT THERAPEUTICS INC (CORT) reported that its Chief Financial Officer, Atabak Mokari, had routine equity-related transactions. On September 1, 2026, he acquired 138 shares of common stock under a purchase plan at a price based on the closing price that day and also received 138 shares underlying unvested restricted stock awards that will vest after one year if he remains the beneficial owner of the purchase-plan shares. On September 2, 2026, 102 shares of common stock were withheld to satisfy tax withholding obligations related to the vesting of restricted stock units; no Rule 10b5-1 trading plan is reported.

CORCEPT THERAPEUTICS INC (CORT) reported insider equity activity by Chief Business Officer Gary Charles Robb. On September 1, 2026, he acquired 164 shares of common stock through a purchase plan and a further 164 shares underlying restricted stock awards, which vest after one year if specified conditions are met. On September 2, 2026, 91 shares were withheld by the company to satisfy tax withholding obligations upon vesting of restricted stock units. He also reports indirect ownership of 39,716 shares held in a revocable trust, plus additional shares in custodial accounts for his children.

CORCEPT THERAPEUTICS INC (CORT) reported that President, Oncology Roberto Wandenkolk Vieira exercised stock options for 58,333 shares of common stock at $21.63 per share on September 2, 2026, then sold 58,333 shares in multiple open-market transactions and had 102 shares withheld to satisfy tax obligations. These sales were made under a Rule 10b5-1 trading plan adopted on June 17, 2026. On September 1, 2026 he also acquired 138 shares through a purchase plan and 138 restricted shares that vest after one year.

CORCEPT THERAPEUTICS INC (CORT) reported that Chief Accounting & Technology Officer Joseph Douglas Lyon had several equity compensation-related transactions. On September 1, 2026, he acquired 130 shares of common stock under a purchase plan at $113.38 per share and received an additional 130 shares of restricted stock awards that carry a one-year cliff vesting condition tied to continued beneficial ownership of the purchase-plan shares. On September 2, 2026, 72 shares of common stock were withheld by the company at a price based on the September 1 closing price of $113.38 to satisfy tax withholding obligations from vesting restricted stock units; no Rule 10b5-1 trading plan is reported.

For CORCEPT THERAPEUTICS INC (CORT), director Kimberly Park reported an option exercise and related share dispositions on August 26, 2026. She exercised 30,000 stock options to acquire 30,000 shares of common stock at an exercise price of $13.49 per share, from a grant that is described as fully exercisable and expires on September 17, 2029. To fund the exercise, 3,315 shares of common stock were withheld by the issuer as payment of the exercise price, and 26,685 shares of common stock were sold at a weighted average price of $122.5471 per share, with actual sale prices ranging from $122.50 to $122.80. After this transaction, 30,000 stock options remain reported as directly owned.

CORCEPT THERAPEUTICS INC (CORT) officer Sean Maduck reported an option exercise and related sales on August 25, 2026. He exercised 30,955 options at an exercise price of $11.35 per share, fully exercisable, and received 30,955 shares of common stock, then sold all 30,955 shares in open-market transactions at weighted average prices around $125–126 per share under a Rule 10b5-1 trading plan adopted on December 8, 2025. Following the option exercise, 169,045 options of the same award type remained outstanding.

Corcept Therapeutics Inc (CORT) director David L. Mahoney reported indirect sales of company common stock on August 18, 2026. A family trust associated with him sold a total of 103,606 shares in multiple open-market transactions at weighted average prices between $116.595 and $119.6775, pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026. The filing also reports 26,147 shares of common stock held indirectly through The Black Dog Private Foundation.

CORCEPT THERAPEUTICS INC (CORT) officer Sean Maduck, President of Corcept Endocrinology, reported an option exercise and related sale on August 14, 2026. He exercised stock options for 3,664 shares of common stock at $8.27 per share and then sold 3,664 shares of common stock at $114.49 per share pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. Following the option exercise, he held 91,986 shares directly, which include unvested restricted stock awards, and also has indirect holdings through various trusts and entities as described in the ownership footnotes, with beneficial ownership of one entity disclaimed except for his pecuniary interest.

CORCEPT THERAPEUTICS INC (CORT) director James N. Wilson reported indirect sales of common stock on August 14, 2026 by the James N. Wilson and Pamela D. Wilson Trust. The trust sold a total of 10,000 shares in multiple open-market transactions at weighted average prices between about $110 and $113 per share, pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026. Wilson has voting power over the trust’s shares but disclaims beneficial ownership except to the extent of his pecuniary interest. Separate indirect holdings entries report 200,000 shares of common stock in each of the James N. Wilson 2025 Grantor Retained Annuity Trust and the Pamela D. Wilson 2025 Grantor Retained Annuity Trust.

CORCEPT THERAPEUTICS INC (CORT) reported insider transactions by Chief Business Officer Gary Charles Robb. On 2026-08-17, he made a bona fide gift of 125 common shares, leaving 13,426 shares held directly, which include multiple unvested restricted stock awards that vest one year after their grant dates, subject to conditions. The same day, an entity associated with him, the Gary Charles Robb TTE Robb Revocable Trust, sold 10,000 common shares at a weighted average price of $116.2572 per share (range $116.00–$116.54), resulting in 39,716 shares held indirectly through the trust. Additional shares are held in custodial accounts for his children under the Uniform Transfers to Minors Act, where he acts as custodian.

Corcept Therapeutics Inc’s Chief Business Officer, Gary Charles Robb, reported several bona fide gift transactions in the company’s common stock on August 12, 2026. He made a gift disposition of 11,530 shares, leaving 13,551 shares held directly, including unvested restricted stock awards. He also reported gifts of 3,000 shares to each of two custodial accounts for his children, which are reported as indirect holdings. Separately, an additional 49,716 shares are held indirectly through the Gary Charles Robb TTE Robb Revocable Trust.

Corcept Therapeutics executive Sean Maduck exercised options for 1,031 shares of common stock at $8.27 per share and sold the same 1,031 shares at a weighted average price of $114.5182 on August 10, 2026. Following the option exercise, he held 95,650 stock options directly, and also holds various indirect positions through trusts and LLCs. The sale was executed under a Rule 10b5-1 trading plan adopted on December 8, 2025. His direct holdings include unvested restricted stock awards that vest one year after their respective grant dates.

Corcept Therapeutics Chief Development Officer William Guyer reported an options exercise and related sales. On 2026-08-10, he exercised a stock option for 16,300 shares of common stock at an exercise price of $21.65 per share, leaving 110,000 options outstanding under that award, which is fully exercisable. The same day, he acquired 16,300 common shares through the exercise and sold 11,530 shares at a weighted average of $113.1772 (actual prices from $112.80 to $113.75) and 4,770 shares at a weighted average of $114.0371 (actual prices from $113.98 to $114.24). The transactions were made pursuant to a Rule 10b5-1 trading plan adopted on November 27, 2024, and his reported holdings include unvested restricted stock awards scheduled to vest on their one-year anniversaries if service conditions are met.

Corcept Therapeutics Chief Development Officer William Guyer exercised stock options to acquire 3,700 shares of common stock at $21.65 per share on August 4, 2026 and sold 3,700 shares at a weighted average price of $113.1248 per share under a Rule 10b5-1 plan adopted on November 27, 2024.

The options exercised were fully exercisable, and 126,300 option shares remained directly held after the transaction. The reported common stock position includes unvested restricted stock awards that each vest 100% on the one-year anniversary of their respective grant dates, subject to specified conditions.

On 2026-08-03, Corcept Therapeutics executive Sean Maduck exercised stock options for 20,305 shares of common stock at $8.27 per share and sold the same number of shares at a weighted average price of $114.7045 (range $114.49–$115.00), pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2025. He continues to hold 96,681 stock options and additional common stock, including unvested restricted stock awards and indirect holdings through trusts and LLCs.

Corcept Therapeutics chief accounting & technology officer Joseph Douglas Lyon reported a sale of 1,540 shares of common stock on August 3, 2026, at $114.16 per share in an open-market or private transaction. After this trade, he holds 5,495 shares, including 200, 178, 398 and 537 shares underlying unvested restricted stock awards granted on September 2, 2025, December 1, 2025, March 2, 2026 and June 1, 2026, which will fully vest on the one-year anniversaries of their grant dates if required conditions are satisfied.

Corcept Therapeutics Chief Financial Officer Mokari Atabak exercised stock options covering 80,000 shares of common stock at an exercise price of $23.06 per share on July 30, 2026, then sold 80,000 shares in multiple open-market or private transactions the same day.

The sales occurred at prices ranging from $105.305 to $120.84 per share. The option was fully exercisable and expires on February 13, 2033, with 95,833 options from this grant remaining. All reported sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025.

Corcept Therapeutics director James N. Wilson reported indirect sales of 10000 shares of common stock on July 15, 2026 by the James N. Wilson and Pamela D. Wilson Trust at weighted-average prices between $86.7777 and $89.4881 per share, pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.

After these sales, that trust held 1093464.0000 shares of common stock, while separate 2025 Grantor Retained Annuity Trusts for James and Pamela Wilson each held 200000.0000 shares indirectly; Wilson has voting power over the trust shares and disclaims beneficial ownership except to the extent of his pecuniary interest.

Corcept Therapeutics Chief Financial Officer Atabak Mokari reported option exercises and share sales in the company’s common stock. On July 15, 2026, he exercised stock options for a total of 40,000 shares at exercise prices of $23.0600 and $19.2600 per share, then sold 40,000 shares in open-market transactions at weighted average prices between $86.7760 and $89.4282 per share, with actual sale prices ranging from $86.20 to $89.43. The sales were made under a Rule 10b5-1 trading plan adopted on December 12, 2025, and the options exercised were fully exercisable.

Corcept Therapeutics Chief Business Officer Gary Charles Robb reported a Form 4 showing a bona fide gift of 600 shares of Corcept Therapeutics common stock on May 27, 2026. The gift carried no sale price. After this transfer, he directly holds 25,081 shares of common stock. He also indirectly holds shares through a revocable trust with 49,716 shares and through two custodial accounts for children, each with 12,571 shares. Footnotes note additional unvested restricted stock awards scheduled to vest on the one-year anniversaries of their respective grant dates, subject to service conditions.

Corcept Therapeutics Chief Development Officer William Guyer reported a combination of option exercises and stock sales in Corcept Therapeutics common stock. He exercised stock options covering 20,000 shares at an exercise price of $21.65 per share, then sold a total of 20,000 shares in open-market transactions at weighted average prices of $93.11 and $93.54, all under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024. Following these transactions, he holds 4,937 common shares directly, plus 130,000 stock options and unvested restricted stock awards that vest on their one-year anniversaries if conditions are met.

Corcept Therapeutics executive Sean Maduck reported option exercises and stock sales. He exercised stock options to acquire 25,000 shares of Common Stock at a strike price of $8.27 per share and sold 25,000 shares in multiple open‑market transactions at weighted average prices around $87–$89 per share under a Rule 10b5-1 trading plan adopted on December 8, 2025.

Following these transactions, he held 9,755 Common shares directly and 116,986 stock options directly, and also reported indirect holdings through trusts and LLCs, some of which he serves as trustee, co‑trustee, member, manager, or president. The filing also notes several unvested restricted stock awards that vest one year after their respective 2025–2026 grant dates if conditions are met.

Corcept Therapeutics director James N. Wilson, through the James N. Wilson and Pamela D. Wilson Trust, sold 10,000 shares of Common Stock on June 16, 2026 in two open-market transactions under a Rule 10b5-1 trading plan adopted on March 12, 2026. The shares were sold at weighted average prices of $83.5708 and $82.6948 per share, with actual prices ranging from $82.13 to $83.935 per share. Following these sales, the trust continues to hold more than 1.09 million shares according to the filing, while two separate 2025 Grantor Retained Annuity Trusts each report indirect holdings of 200,000 shares. Wilson disclaims beneficial ownership of the trust shares except to the extent of his pecuniary interest.

Corcept Therapeutics director David L. Mahoney reported an indirect open-market sale of common stock through The Black Dog Private Foundation. The foundation sold 20,000 shares at a weighted average price of $84.5253 per share, with individual prices ranging from $84.44 to $85.11.

After the sale, the foundation held 26,147 shares of Corcept common stock. A separate indirect holding, the David L. Mahoney and Winnifred C. Ellis 1998 Family Trust, is shown with 1,237,145 shares of common stock following the reported transactions.

Corcept Therapeutics’ Chief Financial Officer Atabak Mokari reported option exercises and related share sales in the company’s common stock. He exercised stock options covering 40,000 shares at an exercise price of $19.26 per share, then sold 40,000 shares in multiple open-market transactions at weighted average prices between approximately $79.40 and $82.18 per share under a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he directly holds 16,130 common shares, which include shares underlying several unvested restricted stock awards scheduled to vest on their one-year anniversaries if service conditions are met.

Corcept Therapeutics’ Chief Development Officer William Guyer reported an exercise-and-sell transaction in company stock. He exercised options to acquire 20,000 shares of common stock at a price of $21.65 per share, then sold 20,000 shares at a weighted average price of $70.60 per share in an open-market transaction.

The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 27, 2024. Following these transactions, he directly holds 3,985 shares of common stock and stock options for 150,000 shares that are fully exercisable, along with additional unvested restricted stock awards scheduled to vest one year after their respective grant dates.

Corcept Therapeutics officer Joseph Douglas Lyon reported routine equity compensation and related tax withholding transactions. On June 1, 2026, he acquired 537 shares of common stock at $0.00 per share as a grant or award, and a separate 537-share acquisition was priced at $70.44 per share under a purchase plan tied to the closing price that day. On June 2, 2026, 269 shares were withheld by Corcept at $70.44 per share to satisfy tax obligations on vesting restricted stock units. After these transactions, he directly held 7,035 common shares, including unvested restricted stock that will vest on one-year anniversaries of their grant dates if conditions are met.

Corcept Therapeutics Chief Development Officer William Guyer reported stock-based compensation and share purchases in company stock. On June 1, 2026, he acquired 877 shares of common stock as a grant at $0.00 per share and an additional 877 shares at $70.44 per share under a purchase plan established within the 2024 Incentive Award Plan. Footnotes show these include shares underlying unvested restricted stock awards, which vest in full one year after their grant dates if service and ownership conditions are met.

Corcept Therapeutics (CORT) officer Sean Maduck reported a series of equity transactions involving company common stock. He exercised stock options for 25,000 shares at $8.27 per share and on the same date sold 25,000 shares in open-market transactions at weighted average prices of about $70–71 per share under a pre-arranged Rule 10b5-1 trading plan. The company also withheld 452 shares valued at $70.44 per share to cover tax obligations on vesting of restricted stock units, which is not an open-market sale. Following these transactions, Maduck holds 9,755 shares directly, plus indirect interests including 10,000 shares in a living trust, 34,000 in MMM 2025, LLC, 40,000 and 20,570 shares in two Grantor Retained Annuity Trusts, and 5,147 shares in Duckhill Capital, LLC, where he disclaims beneficial ownership beyond his pecuniary interest.

Corcept Therapeutics Chief Financial Officer Atabak Mokari reported a set of equity transactions in the company’s common stock. On June 1, 2026, he exercised stock options to acquire 40,000 shares at an exercise price of $19.26 per share, then sold the same 40,000 shares in an open-market transaction at a weighted average price of about $70.00 per share pursuant to a pre-arranged Rule 10b5-1 trading plan. He also received stock awards totaling 634 shares at no cost and an additional 634 shares tied to a purchase plan, while 395 shares were withheld to satisfy tax obligations related to vested restricted stock units. Following these transactions, he directly holds 16,130 shares of common stock, plus unvested restricted stock awards that vest on future one-year anniversaries, subject to continued service and other conditions.

Corcept Therapeutics’ Chief Business Officer Gary Charles Robb reported routine equity compensation and related tax withholding in common stock. On June 1, 2026, he acquired 776 shares under a purchase plan established within the 2024 Incentive Award Plan, with the price based on the closing price that day. The filing also notes restricted stock awards that vest after one year if specific service or ownership conditions are met. On June 2, 2026, 358 shares were withheld by the company at $70.44 per share to satisfy tax obligations tied to vesting restricted stock units, leaving him with 25,681 directly held shares. Additional common stock is held indirectly through a revocable trust and custodial accounts for his children.

Corcept Therapeutics’ Chief Executive Officer, Joseph K. Belanoff, reported a mix of open-market sales and estate-planning transfers involving the company’s common stock. An entity associated with him, the Joseph K. Belanoff and Katherine A. Blenko Revocable Living Trust, sold 12,837 shares at $69.74 per share in an open-market transaction under a pre-arranged Rule 10b5-1 trading plan, leaving 2,565,489 shares held by that trust.

Separately, there were gift transfers totaling 600,000 shares with no consideration. These included 300,000 shares transferred out of the revocable living trust, and 150,000 shares to each of two 2026 Grantor Retained Annuity Trusts for Joseph K. Belanoff and for his spouse, respectively. The filing notes that the CEO disclaims beneficial ownership of certain trust-held shares except to the extent of his pecuniary interest.

Corcept Therapeutics executive Joseph Douglas Lyon reported an open-market sale of 5,000 shares of Common Stock at $65.00 per share on May 27, 2026. After this transaction, he directly owns 6,230 shares of Corcept stock.

A footnote states that his holdings include shares underlying unvested restricted stock awards, including 749 shares granted on June 2, 2025, 200 shares granted on September 2, 2025, 178 shares granted on December 1, 2025, and 398 shares granted on March 2, 2026. These restricted stock awards are scheduled to vest on the one-year anniversary of each grant date if specified conditions are met.

Corcept Therapeutics officer Sean Maduck reported an option exercise and related share sales. He exercised stock options for 75,000 shares of common stock at a $8.27 exercise price, then sold 20,425 shares at $66.1599 and 54,575 shares at $65.3711 in open-market transactions.

The filing notes these sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 8, 2025. After the transactions, he held 29,402 shares directly, plus additional indirect holdings through trusts and LLCs associated with him, which include restricted stock awards that vest over time.

Corcept Therapeutics director James N. Wilson reported indirect gifts of company stock made through family entities. Entities associated with Wilson, including a family trust and James and Pamela Wilson Family Partners, made bona fide gifts totaling 910,078 shares of Corcept common stock at no consideration.

Following these transactions, the James N. Wilson and Pamela D. Wilson Trust held 1,104,543 shares indirectly, and two 2025 Grantor Retained Annuity Trusts each held 200,000 shares. Wilson has voting power over certain shares via voting agreements but disclaims beneficial ownership except to the extent of his pecuniary interest.

Corcept Therapeutics director Leonard G. Baker Jr received a grant of stock options covering 12,500 shares of common stock on May 21, 2026. The options have an exercise price of $59.69 per share and expire on May 21, 2036. They vest in equal monthly installments over one year starting on the monthly anniversary of May 21, 2026, contingent on his continued service, and represent equity-based compensation rather than an open-market trade.

Corcept Therapeutics director Gregg H. Alton received a new stock option award covering 12,500 shares of common stock. The options have an exercise price of $59.69 per share and expire on May 21, 2036, providing long-term equity-based compensation.

The grant vests ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, and each vesting tranche is conditioned on his continued service as of the relevant monthly vesting date.

Corcept Therapeutics director James N. Wilson received a grant of 12,500 stock options on May 21, 2026. Each option allows him to buy Common Stock at an exercise price of $59.69 per share, expiring on May 21, 2036.

The options cover 12,500 underlying shares and were awarded as compensation, not purchased in the open market. They become exercisable in equal monthly installments over one year starting on May 21, 2026, contingent on his continued service on each monthly vesting date.

Corcept Therapeutics director Daniel N. Swisher Jr. received a grant of 12,500 stock options for common stock on May 21, 2026. The options have an exercise price of $59.69 per share and expire on May 21, 2036. They vest in equal monthly installments over one year starting May 21, 2026, conditioned on his continued service.

Corcept Therapeutics director Joshua M. Murray received a grant of stock options covering 12,500 shares of Common Stock. The options have an exercise price of $59.69 per share and expire on May 21, 2036.

The award vests ratably in equal installments on each monthly anniversary of May 21, 2026 over a one-year period, conditioned on his continued service on each monthly vesting date. Following the grant, he holds 12,500 stock options directly, with no sales reported in this filing.

Corcept Therapeutics director David L. Mahoney reported a new stock option grant. He received options to acquire 12,500 shares of Corcept common stock at an exercise price of $59.69 per share, expiring on May 21, 2036.

The options were granted as compensation and involve no open-market buying or selling. According to the terms, they become exercisable in equal monthly installments over one year starting on May 21, 2026, contingent on his continued service on each monthly vesting date.

Corcept Therapeutics director Kimberly Park received a stock option grant for 12,500 shares of common stock. The options were granted on May 21, 2026 with an exercise price of $59.69 per share and expire on May 21, 2036.

The award was reported as a grant or other acquisition and is held directly. Following this transaction, Park holds options covering 12,500 shares. According to the footnote, the options become exercisable in equal monthly installments over a one-year period starting on May 21, 2026, contingent on her continued service on each vesting date.

Corcept Therapeutics’ Chief Business Officer Gary Charles Robb reported several bona fide gifts of Corcept Therapeutics common stock and updated his indirect holdings. On May 13, 2026, he gifted 5,300 shares from his direct holdings and two gifts of 1,000 shares each from custodial accounts for a child, totaling 7,300 shares. After these gifts, he directly holds 24,487 shares, while a custodial account for a child holds 12,571 shares and a revocable trust holds 49,716 shares. Footnotes also note unvested restricted stock awards of 997, 251, 224 and 499 shares, each scheduled to vest in full on the one-year anniversary of their respective grant dates if specified conditions are met.